Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Quetiapine(click to collapse)
1/4 selected
Quetiapine
Seroquel
Second-Generation Antipsychotic
FDA-approved indications
- Schizophrenia (adults; adolescents 13–17 years)
- Acute mania in Bipolar I — mono or adjunct to lithium/divalproex
- Bipolar depression (adults)
- Bipolar I maintenance — adjunct to lithium/divalproex (adults)
Off-label uses
- Insomnia
- Generalized anxiety disorder
- PTSD
Half-life~7 hours (norquetiapine active metabolite: ~12 hours)
Decision GuideWhen to pick each / when to consider an alternative
Quetiapine
Consider when
- Bipolar depression — only SGA FDA-approved as monotherapy for bipolar I and II depression (not just mania)
- Motor-sensitive patient or EPS history — lowest EPS risk among SGAs (akathisia RR 1.01, antiparkinson OR 0.94)
- Parkinson disease or Lewy body dementia psychosis — lowest EPS makes it preferred SGA in movement disorder populations
- Sedation is therapeutically beneficial — dose-stratified H1 blockade; low-dose XR useful for insomnia/anxiety augmentation
- +1 more
Consider an alternative when
- Driving, machinery, or high-attention occupation — significant next-day somnolence impairs psychomotor performance
- History of cataracts or active eye disease — quetiapine-distinctive FDA-labeled cataract warning; periodic slit-lamp exams recommended
- Cardiometabolic risk — second-tier weight gain (~2–3 kg short-term); metabolic monitoring required
- Substance use disorder with sedative misuse pattern — documented quetiapine misuse for sedation/euphoria in SUD populations
- +1 more
| Axis | Quetiapine SGA |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Agranulocytosis / severe neutropenia | |
Cerebrovascular events (elderly w/ dementia) | |
Neuroleptic malignant syndrome (NMS) | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Akathisia / EPS | |
Tardive dyskinesia | |
Seizure risk | |
| Metabolic | |
Weight gain | |
Metabolic (glucose / lipids) | |
| Endocrine | |
Prolactin elevation | |
| Autonomic | |
Anticholinergic burden | |
Orthostatic hypotension | |
| Sensory | |
Visual disturbances (blurred vision, diplopia, lens changes) | |
| Cardiac | |
QTc prolongation | |
| GI | |
Nausea / GI (general) | |
| Hepatic | |
Liver enzymes / hepatotoxicity | |
| Sexual | |
Sexual dysfunction | |
| Interactions | |
CYP interactions / DDI profile | |